NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!
Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.
Start Free »

TEM | NASDAQ

$84.45 $1.87 | 2.26%
SIGNAL:Signal available — unlock to view |2026-09-24 |F&G 83 |RSI 69.2

Company Overview:

Market Cap: $14.86B
Trailing PE: N/A
FWD PE: —
Payout Ratio (TTM): —
52-Week Range: $40.77 - $104.32

2.3 Year TEM Performance Metrics:

Total Return (with DRIP): 109.8% (38.02% CAGR)
Total Return (no DRIP): 109.8% (38.02% CAGR)
Share Price: 109.8% (38.02% CAGR)
Yield on Cost (with DRIP): —
Total Invested: $10,000
Total Value (with DRIP): $20,981
Total Return $ (with DRIP): $10,981
TEM Total Return
1M 3M 6M YTD 1Y 3Y 5Y 10Y
TEM Price Chart
1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)
Pro
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Try it free for 7 days
You save $125.40 (55%)
Most Popular
Premium
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
Ultra
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

TEM Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

TEM - Revenue
TEM Revenue CAGR:1Y: 21.56%2Y: 51.81%5Y: 0.00%10Y: 0.00%
TEM - Earnings Per Share (EPS)
TEM EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Net Income
TEM Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - EBITDA
TEM EBITDA CAGR:1Y: 396.52%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Free Cash Flow
TEM Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Free Cash Flow / Share
TEM Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Operating Income
TEM Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Gross Profit
TEM Gross Profit CAGR:1Y: 26.38%2Y: 84.53%5Y: 0.00%10Y: 0.00%
TEM - Shares Outstanding
TEM Shares Outstanding CAGR:1Y: 5.20%2Y: 8.77%5Y: 0.00%10Y: 0.00%
TEM - Share Buybacks
TEM Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Stock-Based Comp
TEM Stock-Based Comp CAGR:1Y: 141.02%2Y: -66.71%5Y: 0.00%10Y: 0.00%
TEM - Expenses
TEM Expenses CAGR:1Y: 16.62%2Y: 17.69%5Y: 0.00%10Y: 0.00%
TEM - Revenue by Segment
TEM Revenue CAGR:1Y: 21.56%2Y: 51.81%5Y: 0.00%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

TEM - REVENUE: Actual + Estimates
TEM Actual Revenue CAGR:1Y: 21.56%2Y: 51.81%5Y: 0.00%10Y: 0.00%
TEM - EPS: Actual + Estimates
TEM Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - NET INCOME: Actual + Estimates
TEM Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - EBITDA: Actual + Estimates
TEM Actual EBITDA CAGR:1Y: 396.52%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

TEM - Net Profit Margin
TEM Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Gross Profit Margin
TEM Gross Profit Margin CAGR:1Y: 3.97%2Y: 21.55%5Y: 0.00%10Y: 0.00%
TEM - Price to Earnings
TEM Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Price To Sales Ratio
TEM Price To Sales Ratio CAGR:1Y: -22.18%2Y: -6.20%5Y: 0.00%10Y: 0.00%
TEM - Return on Capital Employed
TEM Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Return on Invested Capital
TEM Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Compare stocks side-by-side

Projected Future Returns & Dividends for TEM

Based on past 2.3-year performance, here are TEM growth metrics:

Share price CAGR of +38.02%
Dividend CAGR of +0%

Using TEM CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

TEM (DRIP)TEM - No DRIP
Current Price$84.45$84.45
Start Shares118.41118.41
Start Value$10,000$10,000
  
After 10 years:
Final Share Count118.41118.41
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$84.45$84.45
Total Dividends$0$0
Final Value$10,000$10,000

Estimated Future Value + Dividends - TEM

NOTE: Above numbers are our estimate based on TEM's Dividend and Price CAGR over past 2.3 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
Pro
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Try it free for 7 days
You save $125.40 (55%)
Most Popular
Premium
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
Ultra
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)

Company Info

Tempus AI, Inc. (TEM) had its IPO on 2024-06-14, and is traded on NASDAQ stock exchange.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

TEM website: https://www.tempus.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
Pro
$171 ($14.25/mo) $102.60/yr ($8.55/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Try it free for 7 days
You save $125.40 (55%)
Most Popular
Premium
$288 ($24/mo) $172.80/yr ($14.40/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Try it free for 7 days
You save $211.20 (55%)
Ultra
$576 ($48/mo) $345.60/yr ($28.80/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Try it free for 7 days
You save $422.40 (55%)
Loading signals…

DCF Model — TEM

Value from:
Pay up to today
—
vs current price $84.45
—
Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today
—
grows for the next years
Then mature
—
every future dollar counted back to today
Pile of today-dollars
—
÷ shares
Implied price path
YearFCFImplied price
Sensitivity — fair value: growth ↓ × target return →